GLP1R
ENSG00000112164
Target class
GPCR
Chromosome
6
Approved drugs
7
Clinical candidates (approved and in development)
17
- Approved drugs
- 7
- Clinical candidates (approved and in development)
- 17
- Chemical probe available
- No
- Other names
- GLP-1R
- Target name
- GLP1R
- Gene name
- Glucagon like peptide 1 receptor
- Gene symbol
- GLP1R
- Protein name
- Glucagon-like peptide 1 receptor (GLP-1 receptor) (GLP-1-R) (GLP-1R)
- Gene biotype
- Protein coding
- Gene family
- Glucagon receptor family
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 2
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 4.68
- Tissue specificity (Gini)
- 0.785
- Tissue specificity (tau)
- 0.965
- KEGG gene identifiers
- hsa:2740
- Protein interaction confidence
- 0.842757
- Protein interaction partners
- 37
- R-HSA-381676
- R-HSA-418555
- R-HSA-420092
- End position
- 39091303
- Start position
- 39048781
- Chromosome
- 6
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein .
- Plasma membrane
- PubMed 19861722
- PubMed 26308095
- PubMed 27196125
- PubMed 28514449
- PubMed 7517895
- PubMed 8216285
- PubMed 8405712
- Tissue specificity (tau)
- 0.965248
- Expression inequality (Gini)
- 0.78499
Expression in transcripts per million
- Pancreas
- 4.68
- Heart - Atrial Appendage
- 1.75
- Nerve - Tibial
- 0.91
- Testis
- 0.77
- Heart - Left Ventricle
- 0.59
Expression in transcripts per million
- Pancreas4.68
- Heart - Atrial Appendage1.75
- Nerve - Tibial0.91
- Testis0.77
- Heart - Left Ventricle0.59
- Brain - Caudate (basal ganglia)0.51
- Stomach0.42
- Brain - Hypothalamus0.39
- Lung0.33
- Thyroid0.33
- Brain - Nucleus accumbens (basal ganglia)0.28
- Minor Salivary Gland0.25
- Brain - Putamen (basal ganglia)0.24
- Skin - Sun Exposed (Lower leg)0.22
- Skin - Not Sun Exposed (Suprapubic)0.15
- Artery - Tibial0.14
- Breast - Mammary Tissue0.14
- Brain - Cortex0.13
- Prostate0.1
- Small Intestine - Terminal Ileum0.07
- Adipose - Subcutaneous0.07
- Kidney - Medulla0.06
- Artery - Coronary0.06
- Brain - Anterior cingulate cortex (BA24)0.06
- Adipose - Visceral (Omentum)0.06
And 29 more, listed on the interactive page.
- GO:0007189
- GO:0007190
- GO:0007204
- GO:0005886
- GO:0016020
- GO:0004888
- GO:0005515
- GO:0044508
Related records
Trials (2,076)
- "Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan."
- [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients
- 16-week Flexible vs. 8-week Semaglutide Titration
- 2024 Tirzepatide-Bariatric Surgery
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 3mg Liraglutide for Overweight or Obesity
- 4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes
- 52 Week Trial of Liraglutide in Type 1 Diabetes
- 68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis
- A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus
- A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY
- A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.
- A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus
- A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
- A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease
- A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese
- A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function
- A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
- A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011)
Drugs (17)
- Albiglutide Glucagon-like peptide 1 receptor agonist
- Avexitide Glucagon-like peptide 1 receptor antagonist
- Cotadutide Glucagon-like peptide 1 receptor agonist
- Danuglipron Glucagon-like peptide 1 receptor agonist
- Dulaglutide Glucagon-like peptide 1 receptor agonist
- Efinopegdutide Glucagon-like peptide 1 receptor agonist
- Efpeglenatide Glucagon-like peptide 1 receptor agonist
- Exenatide Glucagon-like peptide 1 receptor agonist
- Liraglutide Glucagon-like peptide 1 receptor agonist
- Lixisenatide Glucagon-like peptide 1 receptor agonist
- Pegapamodutide Glucagon-like peptide 1 receptor agonist
- Pegsebrenatide Glucagon-like peptide 1 receptor agonist
- Retatrutide Glucagon-like peptide 1 receptor agonist
- Semaglutide Glucagon-like peptide 1 receptor agonist
- Survodutide Glucagon-like peptide 1 receptor agonist
- Taspoglutide Glucagon-like peptide 1 receptor agonist
- Tirzepatide Glucagon-like peptide 1 receptor agonist